{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T05:01:20Z","timestamp":1789707680330,"version":"4.0.1"},"reference-count":41,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["52003086"],"award-info":[{"award-number":["52003086"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["51903062"],"award-info":[{"award-number":["51903062"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFC2304205"],"award-info":[{"award-number":["2022YFC2304205"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021171","name":"Basic and Applied Basic Research Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2024A1515220095"],"award-info":[{"award-number":["2024A1515220095"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jconrel.2025.114351","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T21:42:59Z","timestamp":1761342179000},"page":"114351","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"P2","title":["CD47-targeted liposomal chemotherapy upregulates CD47 expression and induces microsatellite instability which enhances cancer immunotherapy"],"prefix":"10.1016","volume":"388","author":[{"given":"Qianqian","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieping","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donger","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Lei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10449","key":"10.1016\/j.jconrel.2025.114351_bb0005","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/S0140-6736(24)00360-X","article-title":"Colorectal cancer","volume":"404","author":"Eng","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2025.114351_bb0010","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1001\/jama.2017.7105","article-title":"Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal Cancer: A randomized clinical trial","volume":"317","author":"Venook","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.jconrel.2025.114351_bb0015","first-page":"2938","article-title":"Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal","volume":"18","author":"Gramont","year":"2000","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.jconrel.2025.114351_bb0020","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.trecan.2024.05.001","article-title":"Advancements in combining targeted therapy and immunotherapy for colorectal cancer","volume":"10","author":"Singh","year":"2024","journal-title":"Trends Cancer"},{"issue":"6","key":"10.1016\/j.jconrel.2025.114351_bb0025","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41575-019-0126-x","article-title":"Immunotherapy in colorectal cancer: rationale, challenges and potential","volume":"16","author":"Ganesh","year":"2019","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"20","key":"10.1016\/j.jconrel.2025.114351_bb0030","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1158\/1078-0432.CCR-22-2176","article-title":"Facts and hopes in colorectal cancer immunotherapy","volume":"29","author":"Foote","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.jconrel.2025.114351_bb0035","doi-asserted-by":"crossref","first-page":"20230117","DOI":"10.1002\/EXP.20230117","article-title":"Cascade loop of ferroptosis induction and immunotherapy based on metal-phenolic networks for combined therapy of colorectal cancer","volume":"5","author":"Li","year":"2025","journal-title":"Exploration"},{"issue":"1","key":"10.1016\/j.jconrel.2025.114351_bb0040","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s40364-024-00640-7","article-title":"Oncological characteristics, treatments and prognostic outcomes in MMR-deficient colorectal cancer","volume":"12","author":"Fan","year":"2024","journal-title":"Biomark. Res."},{"issue":"2","key":"10.1016\/j.jconrel.2025.114351_bb0045","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1053\/j.gastro.2019.08.059","article-title":"Pathways of colorectal carcinogenesis","volume":"158","author":"Nguyen","year":"2020","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.jconrel.2025.114351_bb0050","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1002\/ijc.34946","article-title":"Prognosis and immunotherapy efficacy in dMMR&MSS colorectal cancer patients and an MSI status predicting model","volume":"155","author":"Fu","year":"2024","journal-title":"Int. J. Cancer"},{"issue":"3","key":"10.1016\/j.jconrel.2025.114351_bb0055","doi-asserted-by":"crossref","DOI":"10.1038\/s41571-023-00732-7","article-title":"Neoadjuvant pembrolizumab shows promise in MSI-H\/dMMR solid tumours","volume":"20","author":"Sidaway","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.jconrel.2025.114351_bb0060","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nrclinonc.2009.237","article-title":"Microsatellite instability in colorectal cancer\u2014the stable evidence","volume":"7","author":"Vilar","year":"2010","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.jconrel.2025.114351_bb0065","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.trecan.2016.02.004","article-title":"The immune biology of microsatellite-unstable cancer","volume":"2","author":"Kloor","year":"2016","journal-title":"Trends Cancer"},{"issue":"2","key":"10.1016\/j.jconrel.2025.114351_bb0070","article-title":"Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: from bench to bedside, Biochimica et Biophysica acta (BBA) - reviews on","volume":"1874","author":"Lizardo","year":"2020","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.jconrel.2025.114351_bb0075","doi-asserted-by":"crossref","first-page":"2257098","DOI":"10.1080\/2162402X.2023.2257098","article-title":"Chemoimmunotherapy triggers immune responses targeting microsatellite stable colorectal cancer","volume":"12","author":"Thibaudin","year":"2023","journal-title":"OncoImmunology"},{"issue":"1184","key":"10.1016\/j.jconrel.2025.114351_bb0080","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/postmj\/qgad136","article-title":"Immunotherapy of microsatellite stable colorectal cancer: resistance mechanisms and treatment strategies","volume":"100","author":"Han","year":"2024","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.jconrel.2025.114351_bb0085","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ctrv.2019.04.003","article-title":"Immunotherapy of colorectal cancer: challenges for therapeutic efficacy","volume":"76","author":"Ciardiello","year":"2019","journal-title":"Cancer Treat. Rev."},{"issue":"6","key":"10.1016\/j.jconrel.2025.114351_bb0090","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41568-021-00347-z","article-title":"Systemic immunity in cancer","volume":"21","author":"Hiam-Galvez","year":"2021","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.jconrel.2025.114351_bb0095","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/s41423-021-00634-7","article-title":"HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy","volume":"18","author":"Anderson","year":"2021","journal-title":"Cell. Mol. Immunol."},{"issue":"3","key":"10.1016\/j.jconrel.2025.114351_bb0100","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1093\/annonc\/mdz006","article-title":"The macrophage \u2018do not eat me\u2019 signal, CD47, is a clinically validated cancer immunotherapy target","volume":"30","author":"Takimoto","year":"2019","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.jconrel.2025.114351_bb0105","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.immuni.2020.04.011","article-title":"The CD47-SIRP\u03b1 immune checkpoint","volume":"52","author":"Logtenberg","year":"2020","journal-title":"Immunity"},{"issue":"6","key":"10.1016\/j.jconrel.2025.114351_bb0110","doi-asserted-by":"crossref","first-page":"20240027","DOI":"10.1002\/EXP.20240027","volume":"4","author":"Li","year":"2024","journal-title":"Exploration"},{"key":"10.1016\/j.jconrel.2025.114351_bb0115","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jare.2023.10.009","article-title":"Deciphering the role of CD47 in cancer immunotherapy","volume":"63","author":"Liu","year":"2024","journal-title":"J. Adv. Res."},{"issue":"5473","key":"10.1016\/j.jconrel.2025.114351_bb0120","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1126\/science.288.5473.2051","article-title":"Role of CD47 as a marker of self on red blood cells","volume":"288","author":"Oldenborg","year":"2000","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.jconrel.2025.114351_bb0125","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13045-016-0381-z","article-title":"Is CD47 an innate immune checkpoint for tumor evasion?","volume":"10","author":"Liu","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.jconrel.2025.114351_bb0130","article-title":"Recent progress on nanoadjuvants: from design and assembly to biomedical imaging","author":"Meng","year":"2025","journal-title":"Chin. Chem. Lett."},{"issue":"18","key":"10.1016\/j.jconrel.2025.114351_bb0135","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin\u2019s lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"13","key":"10.1016\/j.jconrel.2025.114351_bb0140","doi-asserted-by":"crossref","first-page":"2311677","DOI":"10.1002\/adfm.202311677","article-title":"Self-promoted targeting delivery of nanodrug through chemotherapeutic upregulation of CD47 for triple negative breast cancer therapy","volume":"34","author":"Liu","year":"2024","journal-title":"Adv. Funct. Mater."},{"issue":"35","key":"10.1016\/j.jconrel.2025.114351_bb0145","doi-asserted-by":"crossref","first-page":"2303835","DOI":"10.1002\/adma.202303835","article-title":"Extracellular vesicles-derived hybrid nanoplatforms for amplified CD47 blockade-based cancer immunotherapy","volume":"35","author":"Tang","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.jconrel.2025.114351_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2023.126539","article-title":"Supermolecular nanovehicles co-delivering TLR7\/8-agonist and anti-CD47 siRNA for enhanced tumor immunotherapy","volume":"251","author":"Shang","year":"2023","journal-title":"Int. J. Biol. Macromol."},{"issue":"2","key":"10.1016\/j.jconrel.2025.114351_bb0155","doi-asserted-by":"crossref","first-page":"152","DOI":"10.26599\/NBE.2024.9290060","article-title":"Advances and prospects in integrated nano-oncology","volume":"16","author":"Jiang","year":"2024","journal-title":"Nano Biomed. Engineer."},{"key":"10.1016\/j.jconrel.2025.114351_bb0160","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.apsb.2022.12.016","article-title":"Building on the backbone of CD47-based therapy in cancer: combination strategies, mechanisms, and future perspectives","volume":"13","author":"Ye","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.jconrel.2025.114351_bb0165","doi-asserted-by":"crossref","first-page":"6308","DOI":"10.1038\/s41467-022-34064-4","article-title":"Metabolic control of CD47 expression through LAT2-mediated amino acid uptake promotes tumor immune evasion","volume":"13","author":"Wang","year":"2022","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.jconrel.2025.114351_bb0170","doi-asserted-by":"crossref","first-page":"E1239","DOI":"10.1073\/pnas.1718197115","article-title":"Chemotherapy induces enrichment of CD47+\/CD73+\/PDL1+ immune evasive triple-negative breast cancer cells","volume":"115","author":"Samanta","year":"2018","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.jconrel.2025.114351_bb0175","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1158\/0008-5472.CAN-17-0307","article-title":"TIMER: A web server for comprehensive analysis of tumor-infiltrating immune cells","volume":"77","author":"Li","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.jconrel.2025.114351_bb0180","doi-asserted-by":"crossref","first-page":"15180","DOI":"10.1038\/ncomms15180","article-title":"A molecular portrait of microsatellite instability across multiple cancers","volume":"8","author":"Cortes-Ciriano","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.114351_bb0185","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1053\/j.gastro.2009.12.064","article-title":"Microsatellite instability in colorectal cancer","volume":"138","author":"Boland","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jconrel.2025.114351_bb0190","doi-asserted-by":"crossref","first-page":"6201","DOI":"10.1038\/s41467-021-26431-4","article-title":"Daily caloric restriction limits tumor growth more effectively than caloric cycling regardless of dietary composition","volume":"12","author":"Pomatto-Watson","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2025.114351_bb0195","doi-asserted-by":"crossref","first-page":"9972","DOI":"10.1021\/acsnano.2c11964","article-title":"Paraptosis inducer to effectively trigger immunogenic cell death for metastatic tumor immunotherapy with IDO inhibition","volume":"17","author":"Zheng","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2025.114351_bb0200","doi-asserted-by":"crossref","first-page":"16056","DOI":"10.1021\/acsnano.3c04778","article-title":"Chimeric peptide engineered bioregulator for metastatic tumor immunotherapy through macrophage polarization and phagocytosis restoration","volume":"17","author":"Chen","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.jconrel.2025.114351_bb0205","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1038\/s41416-024-02696-6","article-title":"First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer-the randomised METIMMOX trial","volume":"130","author":"Ree","year":"2024","journal-title":"Br. J. Cancer"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925009654?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365925009654?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T08:56:46Z","timestamp":1780822606000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365925009654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":41,"alternative-id":["S0168365925009654"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.114351","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CD47-targeted liposomal chemotherapy upregulates CD47 expression and induces microsatellite instability which enhances cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2025.114351","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"114351"}}